Washington-based Chase Pharmaceuticals has appointed Douglas Ingram as its new chief executive officer to replace John Siebert, who will continue working with the company in an advisory capacity.
He brings to the role nearly 20 years of experience in biotech, pharmaceutical and medical devices leadership.
Prior to serving as president of Allergan, Ingram directed the company’s operations in Europe, the Middle East and Africa and was responsible for various aspects of its global organisation including regulatory affairs and external communications.
Ingram said: “I am privileged to lead Chase Pharmaceuticals as we execute an elegant approach to the development of new Alzheimer’s treatments.
“Our goal is to build a strong CNS biopharmaceutical company to improve the lives of the millions of patients and their families burdened by this devastating disease. We have an important mission and I am excited to play a leadership role in this journey.”
As CEO, Ingram will focus on the direction of Chase Pharmaceuticals’ development and commercialisation of improved treatments for neurodegenerative disorders, in particular its current work on symptomatic treatment of Alzheimer’s disease.
Greg Parekh, chairman of Chase Pharmaceuticals, said: “Doug has a proven track record of disruptive approaches, building strong teams and delivering above-market performance … I am confident that Doug will successfully develop Chase to its fullest potential.”